Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Cancer
-                  anti-Angiopoietin-2, mAb (rec.) (blocking) (Angy-2-1) (preservative free) anti-Angiopoietin-2, mAb (rec.) (blocking) (Angy-2-1) (preservative free)AG-27B-0016PF AG-27B-0016PF-C100 100 µg CHF 420.00AG-27B-0016PF-C500 500 µg CHF 1’140.00AG-27B-0016PF-M001 1 mg CHF 2’040.00  
-                  anti-Angiopoietin-2, mAb (rec.) (blocking) (Angy-2-1) anti-Angiopoietin-2, mAb (rec.) (blocking) (Angy-2-1)AG-27B-0016 AG-27B-0016-TRIAL 25 µg CHF 150.00AG-27B-0016-C100 100 µg CHF 420.00  
-                  anti-IDO1 (human), pAb anti-IDO1 (human), pAbAG-25A-0029 AG-25A-0029-TRIAL 25 µg CHF 140.00AG-25A-0029-C100 100 µg CHF 450.00  
-                  anti-IDO1 (mouse), pAb anti-IDO1 (mouse), pAbAG-25A-0032 AG-25A-0032-TRIAL 25 µg CHF 140.00AG-25A-0032-C100 100 µg CHF 450.00  
-                  anti-Nampt (Visfatin/PBEF), mAb (OMNI379) anti-Nampt (Visfatin/PBEF), mAb (OMNI379)AG-20A-0034 AG-20A-0034-C050 50 µg CHF 290.00AG-20A-0034-C100 100 µg CHF 410.00  
-                 
-                 
-                 
 

![Immunofluorescence using anti-PARP-10 [ARTD10] (human), mAb (5H11). <b>Method:</b> T47D mammary carcinoma cells were stained by indirect immunofluorescence and analysed. Prior to fixation and staining, the cells were treated with or without 50nm leptomyci](https://adipogen.com/media/catalog/product/cache/be9249d907792254897dc476f14d8e2a/a/g/ag-20t-0004-if.png)